Cytomx Therapeutics, INC. (CTMX) — 10-Q Filings

10-Q Filings (6)

• CytomX Q3 Revenue Plunges 82% Amidst Net Loss, Bolstered by Equity Raise — Nov 6, 2025 Risk: high
  CytomX Therapeutics, Inc. (CTMX) reported a significant decline in revenue and a net loss for the three months ended September 30, 2025, with revenues plummetin
• CytomX Losses Widen Amid R&D Spend, Revenue Dip — Aug 7, 2025 Risk: high
  CytomX Therapeutics, Inc. reported a net loss of $39.5 million for the three months ended June 30, 2025, a significant increase from the net loss of $28.7 milli
• CytomX Therapeutics Files Q1 2025 10-Q — May 12, 2025 Risk: medium
  CytomX Therapeutics, Inc. filed its 10-Q for the period ending March 31, 2025. The company reported on its ongoing collaborations, including agreements with Amg
• CytomX Therapeutics Files Q3 2024 10-Q — Nov 7, 2024 Risk: medium
  CytomX Therapeutics, Inc. filed its Q3 10-Q report for the period ending September 30, 2024. The company reported financial results and provided updates on its
• CytomX Therapeutics Q2 2024 Update — Aug 8, 2024 Risk: medium
  CytomX Therapeutics, Inc. filed its Q2 10-Q report for the period ending June 30, 2024. The company's financial statements reflect its ongoing operations in the
• CytomX Therapeutics Files 10-Q for Period Ending March 31, 2024 — May 8, 2024 Risk: medium
  CytomX Therapeutics, Inc. (CTMX) filed a Quarterly Report (10-Q) with the SEC on May 8, 2024. CytomX Therapeutics, Inc. filed a 10-Q report for the quarter ende

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX